Memory B-cell depletion is a feature of HIV-2 infection even in the absence of detectable viremia

Rita Tendeiro\textsuperscript{a}, Sofia Fernandes\textsuperscript{a}, Russell B. Foxall\textsuperscript{a}, José M. Marcelino\textsuperscript{b,c}, Nuno Taveira\textsuperscript{b,d}, Rui S. Soares\textsuperscript{a}, António P. Baptista\textsuperscript{a}, Rita Cavaleiro\textsuperscript{a}, Perpétua Gomes\textsuperscript{d,e,f}, Rui M.M. Victorino\textsuperscript{a,g} and Ana E. Sousa\textsuperscript{a}

Objective: Memory B-cell loss has long been recognized as an important contributor to HIV immunodeficiency. HIV-2 infection, which is characterized by a slow rate of progression to AIDS and reduced to undetectable viremia, provides a unique model to investigate B-cell disturbances.

Design and methods: B-cell subsets were evaluated in 38 HIV-2-infected individuals, along with markers of T-cell activation and serum levels of immunoglobulins and a major B-cell homeostatic cytokine, B-cell activating factor (BAFF). Untreated HIV-1-infected and seronegative control individuals were studied in parallel. Statistical analysis was performed using Mann–Whitney tests and Spearman’s correlations.

Results: We found that HIV-2 was associated with significant depletion of both unswitched (CD27\textsuperscript{+}IgD\textsuperscript{+}) and switched (CD27\textsuperscript{+}IgD\textsuperscript{−}) memory B-cells that directly correlated with T-cell activation, even in individuals with undetectable plasma viral load. Nevertheless, the presence of detectable viremia, even at low levels, was associated with significant memory B-cell loss and higher BAFF levels. Moreover, these alterations were not recovered by antiretroviral-therapy, as treated HIV-2-infected patients showed more pronounced B-cell disturbances, possibly related to their extended length of infection.

Conclusion: These first data regarding B-cell imbalances during HIV-2 infection show that, irrespective of viremia, prolonged HIV infection leads to irreversible damage of memory B-cell homeostasis.

Introduction

HIV-1 infection is associated with progressive impairment of specific humoral responses and loss of memory B-cells that are only partly recovered by antiretroviral therapy (ART) \cite{1,2,3,4}. These B-cell disturbances have been linked to the persistent heightened state of immune activation associated with HIV-1 infection \cite{3,4,5}. In fact,
polyclonal B-cell activation with marked hypergammaglobulinemia is usually observed in acute HIV-1 infection [6], persisting throughout the chronic phase of the disease [3,5]. HIV-1 proteins, particularly gp120 [7,8] and Nef [9,10], have also been shown to induce intrinsic B-cell functional defects.

HIV-2 infection is characterized by a much slower rate of disease progression, with low-to-undetectable viremia, providing a unique naturally occurring model of attenuated disease to investigate B-cell disturbances in HIV pathogenesis. HIV-2 plasma viral load is usually low to undetectable throughout the entire disease course [11,12]. This low viremia is thought to account for the low transmission rates [13,14] contributing to the confinement of HIV-2 infection to west Africa and connected countries, such as Portugal [15,16]. Additionally, HIV-2 has limited impact on the mortality of infected adults, even in rural west African areas, where its prevalence has reached 8–10% [17–19]. In agreement, a prospective study of a French HIV-2 cohort has revealed that the rate of CD4 decline is, on average, 10 times lower than in HIV-1-infected individuals, leading to a median time of progression to AIDS of more than 20 years [20].

We have previously shown that as for HIV-1, CD4 depletion is directly linked to increased viral activation in HIV-2-infected individuals [12,21]. Moreover, HIV-2 infection also induces polyclonal B-cell activation, as demonstrated by the frequently observed hypergammaglobulinemia [22,23] and hyperplastic lymph nodes [24]. Of note, several studies have suggested a better ability of HIV-2-infected, in comparison with HIV-1-infected individuals, to generate and preserve significant levels of circulating HIV-neutralizing antibodies during the chronic phase of the disease [23,25–28]. This finding is thought to be mainly related to particular conformations of the HIV-2 envelope proteins that favour triggering of potent neutralizing antibody responses [23,25–30], although the possibility of a superior function of the B-cell compartment in HIV-2-infected patients has not been formally evaluated.

Here, we report the first data on memory B-cell imbalances during HIV-2 infection. We found an unexpected major depletion of both switched and unswitched memory B-cells not recovered by ART in HIV-2-infected individuals, suggesting that, irrespective of viremia, prolonged HIV infection leads to irreversible damage of memory B-cell homeostasis.

**Methods**

**Studied cohorts**

The study involved 38 HIV-2-infected, 20 HIV-1-infected and 16 noninfected (seronegative) individuals. Table 1 details the cohort clinical and epidemiological data. HIV-infected patients were followed at the Hospital de Santa Maria, Lisbon, and had no ongoing opportunistic infections or tumours. All patients gave written informed consent for blood sample collection and processing. The study was approved by the Ethical Board of the Faculty of Medicine, University of Lisbon. All HIV-1-infected individuals were therapy naive. The HIV-2 cohort included 10 patients on ART that did not differ significantly from the untreated HIV-2-infected patients in respect to viremia and proviral DNA levels (Supplemental_Digital_Content, Table 1, http://links.lww.com/QAD/A229). HIV-2-infected individuals on ART showed significantly reduced CD4+ T cells, both in relation to seronegatives and untreated HIV-2-infected patients (Supplemental_Digital_Content, Table 1, http://links.lww.com/QAD/A229), in agreement with previous reports on weak virologic and immunological responses to ART in HIV-2-infected individuals [20,31].

**Plasma viral load and proviral DNA assessment**

HIV viremia was quantified by real time (RT)-PCR for both HIV-1-infected (detection threshold: 40 RNA

---

**Table 1. Clinical and epidemiological characteristics of the studied cohorts.**

<table>
<thead>
<tr>
<th>Seronegatives*</th>
<th>HIV-2*</th>
<th>HIV-1*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number (men/women)</td>
<td>16 (6/10)</td>
<td>38 (14/24)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>44 (27–57)</td>
<td>56 (19–76)**</td>
</tr>
<tr>
<td>White/black</td>
<td>15/1</td>
<td>21/17</td>
</tr>
<tr>
<td>CD4+ T-cells (%)</td>
<td>59 (40–77)</td>
<td>32 (4–66)***</td>
</tr>
<tr>
<td>CD4+ T-cells/μl</td>
<td>818 (518–1312)</td>
<td>470 (52–1511)***</td>
</tr>
<tr>
<td>Viremia, HIV RNA copies/ml</td>
<td>–</td>
<td>200 (200–34 x 10^3)***</td>
</tr>
<tr>
<td>Proviral DNA, copies/10^6 PBMC</td>
<td>–</td>
<td>78 (5–1033)</td>
</tr>
<tr>
<td>B-cells (%)</td>
<td>6 (3–13)</td>
<td>7 (3–20)</td>
</tr>
<tr>
<td>B-cells/μl</td>
<td>120 (63–369)</td>
<td>133 (30–369)</td>
</tr>
</tbody>
</table>

PBMC, peripheral blood mononuclear cells. Data are expressed as median, with limits in brackets. Statistical analysis was performed with Mann–Whitney tests.

* A distinct cohort was used for serum B-cell activating factor quantification, as described in Fig. 3.

**P < 0.05.

***P < 0.001 in comparison with seronegatives.

*P < 0.05.

**P < 0.01 for comparisons between infected cohorts.
copies/ml, Roche, Basel, Switzerland) and HIV-2-infected (detection threshold: 200 RNA copies per millilitre, as described [31]) individuals. Viremia was, as expected [12,20,32], significantly lower in HIV-2-infected than in untreated HIV-1-infected patients (Table 1).

HIV-1 and HIV-2 total viral DNA (integrated and nonintegrated DNA species) were quantified, as previously described [33]. Briefly, DNA was extracted from 5 × 10⁶ peripheral blood mononuclear cell (PBMC) and total viral DNA was quantified using real-time PCR assays amplifying highly conserved regions in HIV-1 and HIV-2 gag (detection range: seven orders of magnitude; sensitivity: five copies). Cutoff values of the tests were considered for statistical analysis in cases in which detection was below these levels.

Flow cytometry
PBMC were isolated immediately after venopuncture by Ficoll–Hypaque density gradient centrifugation (Sigma, St. Louis, Missouri, USA) and surface stained as previously described [34]. Briefly, after isolation PBMC were washed and surface stained for 20 min at room temperature with the following monoclonal antibodies (mAb) (clone specified in brackets): fluorescein isothiocyanate (FITC)-conjugated CD10 (CB-CALLA), phycoerythrin (PE)-Cy7-conjugated CD19 (HIB19) and allophycocyanin (APC)-conjugated CD27 (O323) from eBioscience (San Diego, California, USA), as well as with PE-conjugated immunoglobulin D (IgD) (IA6–2) and APC-Cy7-conjugated CD3 (SK7) from BD Biosciences (San Jose, California, USA). At least 150 000 events were acquired using a CANTO flow cytometer (BD Biosciences) and analyzed using FlowJo software (version 8.5.3, TreeStar, Inc., Ashland, Oregon, USA). Cells were successively gated on lymphocytes, according to forward/side scatter characteristics and B-cells (CD19⁺CD3⁻), which were then analyzed in terms of CD27 and IgD expression, as illustrated in Fig. 1. T-cell activation was assessed as previously described [34] using the following mAbs (clone specified in brackets): FITC-conjugated HLA-DR (L243), PerCP-conjugated CD4 (SK3) and APC-Cy7-conjugated CD3 (SK7) from BD Biosciences; and PE-conjugated CD38 (HI122) and APC-conjugated CD8 (RPA-T8), both from eBioscience.

Interleukin-7, B-cell activating factor, total serum immunoglobulin, β2-microglobulin and specific antibodies quantifications
Serum interleukin (IL)-7 and B-cell activating factor (BAFF) were quantified by ELISA (R&D Systems, Minneapolis, Minnesota, USA), according to the manufacturer’s specifications. Samples were assayed in duplicate.

Total immunoglobulin G (IgG), immunoglobulin A (IgA) and immunoglobulin M (IgM) were quantified by immunonephelometry (Beckman–Coulter, Brea, California, USA) and β2-microglobulin by immunoturbidimetry (Roche Diagnostics, Indianapolis, Indiana, USA) at the clinical laboratory of the Hospital de Santa Maria.

Quantification of specific antibodies against HIV-2 env glycoproteins gp36 and gp125 (C2–C3 region) was performed using a dual-antigen ELISA, as previously described [29]. The results of the assay were expressed quantitatively as ODclinical sample/ODcutoff (S/CO) ratios. For ratio values of greater than 1, the samples were considered seroreactive.

Statistical analysis
Statistical analysis was performed with Mann–Whitney tests and Spearman’s correlations using GraphPad Prism.

Fig. 1. Flow-cytometric analysis of B-cell subsets. Representative dot-plots of the flow cytometric analysis of circulating B cells (CD19⁺CD3⁻), according to the surface expression of IgD and CD27. Age-matched individuals are shown. Data refer to one seronegative (31 years old, 778 CD4⁺ T cells/μl), one untreated HIV-2-infected (34 years old, 321 CD4⁺ T cells/μl, undetectable viremia), one treated (ART) HIV-2-infected (34 years old, 326 CD4⁺ T cells/μl, undetectable viremia) and one untreated HIV-1-infected (30 years old, 306 CD4⁺ T cells/μl, 1814256 HIV-1 RNA copies/ml) individuals. Numbers inside quadrants represent the proportion of B cells expressing the respective markers. ART, antiretroviral therapy; IgD, Immunoglobulin D.
We investigated here, for the first time, memory B-cell disturbances during HIV-2 infection. HIV-2-infected patients showed no significant alterations in either the total numbers of peripheral blood B-cells or the proportion of B-cells within total PBMC as compared with seronegative individuals (Table 1). Memory B-cell populations were assessed by flow cytometry within PBMC, as illustrated in Fig. 1.

A marked reduction in the proportion of memory B-cells (CD27<sup>+</sup>) was found in HIV-2-infected individuals (Figures 1 and 2a), both in comparison with seronegative and HIV-1-infected individuals with similar degrees of CD4 depletion (Table 1). Of note, numbers of circulating memory B-cells were significantly lower in HIV-2 individuals than in seronegatives (Supplemental_Digital_Content, Figure 1, http://links.lww.com/QAD/A229).

Memory B-cell loss was strongly correlated with CD4 depletion and immune activation, assessed both in terms of T-cell activation and serum β2-microglobulin, in HIV-2-infected individuals (Table 2 and Supplemental_Digital_Content, Table 2, http://links.lww.com/QAD/A229 for absolute B-cell counts). In agreement, this loss was significantly more marked in advanced as compared to early stage HIV-2 disease (less or more than 350 CD4<sup>+</sup> T-cells; Figure 2b and Supplemental_Digital_Content, Figure 1B for absolute B-cell counts, http://links.lww.com/QAD/A229).

Additionally, an association was found between memory B-cell loss and viremia (Table 2 and Supplemental_Digital_Content, Table 2 for absolute B-cell counts, http://links.lww.com/QAD/A229). Accordingly, HIV-2-infected patients with measurable viremia featured significantly less memory B-cells than those with undetectable viremia (Fig. 2b and Supplemental_Digital_Content, Figure 1B, http://links.lww.com/QAD/A229), despite the highest measured level being only 34314 RNA copies per millilitre (Table 1).

No such correlations were found in the untreated HIV-1 cohort (Table 2 and Supplemental_Digital_Content, Table 2 for absolute B-cell counts, http://links.lww.com/QAD/A229), despite the viremia being, on average, 2-log higher than in the HIV-2 cohort (Table 1). The differences in memory B-cell loss between the two infections were particularly marked when groups of infected individuals in advanced disease stage or with detectable viremia were compared (Supplemental_Digital_Content, Figure 2A and Tables 3 and 4, http://links.lww.com/QAD/A229).

In spite of the distinct viremia, comparable amounts of cell-associated viral load (proviral DNA) were observed in the two infections (Table 1; Supplemental_Digital_Content, Tables 3 and 4, http://links.lww.com/QAD/A229), as previously reported [31–33]. Notably, no significant correlations were found between levels of proviral DNA and frequency of memory B-cells in either infection (P > 0.05).

HIV-1 has also been associated with an expansion of peripheral blood immature (CD27<sup>−</sup>CD10<sup>+</sup>) B-cells that was shown to be directly correlated with circulating IL-7 levels and suggested to arise from lymphopenia-induced IL-7-mediated homeostasis [53]. We have previously shown that serum IL-7 is significantly increased in HIV-2 infection in strong association with CD4<sup>+</sup> T-cell levels [39]. In fact, we also observed a significant expansion of CD27<sup>−</sup>CD10<sup>+</sup> B-cells in HIV-2-infected patients (median: 1.09%, range: 0.09–7.95; P = 0.0007), as compared to seronegatives (median: 0.39%, range: 0.10–1.41). Nevertheless, we found no significant correlations between the frequency of CD27<sup>−</sup>CD10<sup>+</sup> B-cells with serum IL-7 levels in the HIV-2 cohort (n = 35; serum IL-7 levels median: 12.21 pg/ml, range: 2.26–28.70; r = 0.1859, P = 0.2850) suggesting that other mechanisms are modulating the expansion of immature B-cells during HIV-2 infection.

Although, the HIV-2 cohort included 10 individuals under ART (Supplemental_Digital_Content, Table 1, http://links.lww.com/QAD/A229), the B-cell imbalances were also found when only untreated individuals were compared to seronegatives (Supplemental_Digital_Content, Figure 3A, http://links.lww.com/QAD/A229). Moreover, ART-treated patients showed a significantly lower frequency of memory B-cells than their untreated counterparts (Supplemental_Digital_Content, Figure 3A, http://links.lww.com/QAD/A229), which may reflect their prolonged infection, as estimated below, and the poor immunological recovery under ART typically observed in HIV-2 infection (Supplemental_Digital_Content, Table 1, http://links.lww.com/QAD/A229).

Overall, HIV-2 infection was associated with progressive loss of memory B-cells.

**Both switched and unswitched memory B-cells were lost during HIV-2 disease**

The CD27<sup>+</sup> B-cell subset can be further subdivided in terms of class-switched and unswitched immunoglobulin production, assessed here by IgD surface expression [35].
Fig. 2. Memory B-cell subsets frequency in HIV-2 infection. (a) Relative proportions of total memory cells (CD27+, top graph), switched memory cells (CD27+IgDneg, middle graph) and unswitched memory cells (CD27+IgD+, bottom graph), within total B-cells, in the HIV-2 cohort, as well as seronegative (Seroneg) and HIV-1-infected individuals. (b) HIV-2-infected patients were further subdivided according to disease stage (early: >350 CD4+ T-cells/µl; late: <350 CD4+ T-cells/µl) and levels of plasma viral load (aviremic: undetectable plasma viral load; viremic: detectable). The frequencies of the B-cell subsets described in (a) were compared between seronegatives and all subgroups of HIV-2-infected individuals. Each dot represents one individual and bars indicate median. Filled circles refer to ART-treated individuals. Statistical analysis was performed using the Mann–Whitney test and the significant P values are shown. ART, antiretroviral therapy.
Class-switched memory B-cells (CD27\(^+\)IgD\(^{\text{neg}}\)) are mainly generated in germinal centres and play a key role in adaptive immune responses, whereas unswitched CD27\(^+\)B-cells are thought to include largely marginal zone B-cells, and are known to play a role in protection against encapsulated bacteria [35].

Memory B-cell loss observed during HIV-2 disease was related to a pronounced depletion of cells with a class-switched phenotype (Figs. 1 and 2a; Supplemental_Digital_Content, Figure 1 for absolute counts, http://links.lww.com/QAD/A229), which showed strong positive correlations with markers of disease progression (Table 2 and Supplemental_Digital_Content, Table 2 for absolute B-cell counts, http://links.lww.com/QAD/A229). No such correlations were observed in the HIV-2 cohort (Table 2 and Supplemental_Digital_Content, Table 2 for absolute B-cell counts, http://links.lww.com/QAD/A229), but was not documented for HIV-1 infection (Supplemental_Digital_Content, Figure 2B, http://links.lww.com/QAD/A229). Notably, despite both infections exhibiting similar levels of immune activation (Table 2), as previously reported [12], the impairment in switched memory B-cell preservation seemed to be more strongly linked to the persistent immune activation in HIV-2 than in HIV-1 infection (Table 2 and Supplemental_Digital_Content, Table 2 for absolute B-cell counts, http://links.lww.com/QAD/A229).

Conversely, the loss of unswitched (IgD\(^+\)) memory B-cells in HIV-2 infection was comparable to that observed in HIV-1 infection (Fig. 2a and Supplemental_Digital_Content, Figure 1A for absolute counts, http://links.lww.com/QAD/A229). This loss was positively correlated with markers of disease progression in both HIV-1 and HIV-2 cohorts (Table 2 and Supplemental_Digital_Content, Table 2 for absolute B-cell counts, http://links.lww.com/QAD/A229), being significantly more pronounced in patients with CD4\(^+\)T-cell counts below 350 cells/\(\mu\)l or detectable viremia (Fig. 2b; Supplemental_Digital_Content, Figure 1B and Figure 2C, http://links.lww.com/QAD/A229).

Of note, both switched and unswitched memory B-cells were markedly decreased in HIV-2-infected patients under ART (Supplemental_Digital_Content, Figure 3B and 3C, respectively, http://links.lww.com/QAD/A229), which may be, at least in part, related to the more prolonged length of disease. Given the slow rate of CD4 decline, it is expected that HIV-2-infected patients have been infected for much longer than untreated HIV-1-infected individuals. Our estimation of the length of follow-up, for those patients for whom these data were available, was in agreement with this possibility (median months for treated HIV-2: 97, range: 8–242, n = 10; untreated HIV-2: 71, range: 24–235, n = 16; untreated HIV-1: 75, range: 13–184, n = 9).

### Table 2. Relationship between B-cell subsets and markers of disease progression.

<table>
<thead>
<tr>
<th>HIV-2 (n = 38)</th>
<th>% B-cells</th>
<th>%CD27(^+)IgD(^+)</th>
<th>%CD27(^+)IgD(^{\text{neg}})</th>
<th>%CD27(^+)IgD(^{\text{neg}})</th>
<th>%CD27(^+)IgD(^{\text{neg}})</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4(^+) T-cells/(\mu)l</td>
<td>−0.222; 0.8947</td>
<td>−0.5551; 0.0003</td>
<td>0.6001; &lt;0.0001</td>
<td>0.7591; &lt;0.0001</td>
<td>0.5717; 0.0002</td>
</tr>
<tr>
<td>Viremia, HIV RNA cp/ml</td>
<td>0.0167; 0.9209</td>
<td>0.3697; 0.0223</td>
<td>−0.4214; 0.0084</td>
<td>−0.4250; 0.0078</td>
<td>−0.3981; 0.0133</td>
</tr>
<tr>
<td>%HLA-DR(^+)CD38(^+) within CD4(^+)</td>
<td>0.2132; 0.1988</td>
<td>0.4842; 0.0021</td>
<td>−0.5541; 0.0003</td>
<td>−0.7152; &lt;0.0001</td>
<td>−0.5036; 0.0013</td>
</tr>
<tr>
<td>%HLA-DR(^+)CD38(^+) within CD8(^+)</td>
<td>0.1664; 0.3180</td>
<td>0.4223; 0.0067</td>
<td>−0.4641; 0.0033</td>
<td>−0.6157; &lt;0.0001</td>
<td>−0.4224; 0.0082</td>
</tr>
<tr>
<td>β2-microglobulin (mg/l)</td>
<td>−0.0327; 0.8638</td>
<td>0.5994; 0.0006</td>
<td>−0.6416; 0.0001</td>
<td>−0.7961; &lt;0.0001</td>
<td>−0.5877; 0.0006</td>
</tr>
</tbody>
</table>

Spearman’s correlation coefficient was used and results are expressed as r; P, with significant correlations in bold.

\(^{a}\)Frequency of cells coexpressing the activation markers HLA-DR and CD38 within CD4\(^+\) and CD8\(^+\) T-cells (median, range). HIV-2: 3.4, 0.4–23.5 (CD4) and 15.1, 0.6–69.5% (CD8); untreated HIV-1: 5.5, 0.3–34.8 (CD4) and 23.7, 1.4–62.2% (CD8). No significant differences were found between infected cohorts, which exhibited significantly higher levels than seronegative controls (CD4: 1.1, 0.7–2.0%; CD8: 2.7, 1.3–22.7%).

\(^{b}\)β2-microglobulin serum levels were assessed for 30 HIV-2 (median: 2.6 mg/l, range: 1.1–7.8 mg/l) and 14 HIV-1-infected (median: 2.4 mg/l, range: 1.3–6.0 mg/l) individuals, with no statistically significant differences being observed between cohorts.

Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Notably, B-cell imbalances did not correlate with age in all the cohorts ($P > 0.05$).

Altogether, progressive memory B-cell loss during HIV-2 infection was due to a depletion of both switched and unswitched memory B-cells.

**Memory B-cell imbalances did not translate into decreased immunoglobulin levels**

Notwithstanding the generalized memory B-cell loss, most HIV-2-infected patients showed increased levels of IgG, as previously reported [22,23], while maintaining IgM and IgA titers within the normal range (Supplemental_Digital_Content, Figure 4A, http://links.lww.com/QAD/A229).

Additionally, we quantified serum levels of antibodies against HIV-2 env glycoproteins gp36 and gp125 (C2-C3 region) as previously described [29]. No significant differences were observed in specific antibody levels when HIV-2-infected patients were subdivided, either according to CD4$^+$ T-cell counts or viremia ($P > 0.05$). Nevertheless, although IgG, IgM and IgA levels did not significantly differ between untreated and treated HIV-2 infection, HIV-2-infected individuals under ART had significantly lower levels of specific antibodies against the C2-C3 region of gp125 (Supplemental_Digital_Content, Figure 4B, http://links.lww.com/QAD/A229).

Overall, HIV-2-infected patients did not feature major impairments in total immunoglobulin levels or HIV-2-specific antibody production, despite the observed memory B-cell imbalances.

**B-cell activating factor levels increased during HIV-2 disease, particularly in the presence of detectable viremia, in direct association with memory B-cell disturbances**

B-cell survival and differentiation rely on BAFF, a cytokine mainly produced by stromal cells, monocytes and T-cells, detectable in the serum of healthy individuals [36–38]. BAFF levels were significantly higher in the HIV-2 cohort, as compared with seronegatives (Fig. 3a). Notably, a direct correlation was found between serum BAFF levels and viremia in the HIV-2 cohort ($r = 0.4939$, $P = 0.0195$, $n = 12$), and in agreement, significantly higher BAFF titres were observed in HIV-2-infected patients with detectable viremia, both in relation to aviremic individuals and seronegatives (Fig. 3B, Supplemental_Digital_Content, Figure 5A, http://links.lww.com/QAD/A229); this was observed in untreated as well as in ART-treated HIV-2 groups (Supplemental_Digital_Content, Figure 5B, http://links.lww.com/QAD/A229). A similar relationship between serum BAFF levels and viremia was observed in the HIV-1 cohort ($r = 0.5916$, $P = 0.0428$, $n = 12$; and Supplemental_Digital_Content, Figure 5A, http://links.lww.com/QAD/A229).

Although no significant correlations were found between serum BAFF levels and the degree of CD4 depletion, advanced HIV-2 disease (less than 350 CD4$^+$ T-cells/$\mu$L) was associated with higher BAFF levels (Fig. 3b). Moreover, HIV-2-infected individuals under ART showed a significant increase in BAFF as compared to seronegatives irrespective of viremia possibly related to their reduced CD4 cell counts (Supplemental_Digital_Content, Figure 5B, http://links.lww.com/QAD/A229).

Of note, HIV-2-infected patients showed significant inverse correlations between serum BAFF levels and frequency of total ($r = -0.5456$, $P = 0.0086$, $n = 22$) and switched memory B cells ($r = -0.5247$, $P = 0.0122$, $n = 22$). Such correlations were not found in the HIV-1 cohort ($P > 0.05$).

In conclusion, HIV-2 infection was associated with an increase in serum BAFF levels that correlated with memory B-cell loss.

**Discussion**

We report here, for the first time, that despite its relatively benign course and low viremia, HIV-2 disease progression was associated with major losses of both switched and unswitched memory B-cells and elevated serum BAFF levels. Additionally, we found that these disturbances were not recovered by ART.

We showed that memory B-cell levels negatively correlated with T-cell activation in HIV-2-infected individuals, suggesting a close association between B-cell disturbances and hyperimmune activation, even in the context of low viremia. This is in agreement with previous reports associating B-cell dysregulation during HIV-1 disease with hyperimmune activation [3,4].

In order to account for the possible impact of CD4 lymphopenia on B-cell disturbances, we compared HIV-1-infected and HIV-2-infected individuals with similar degrees of CD4 depletion, despite differences in length of disease and viremia. Importantly, memory B-cell loss, particularly of the switched memory pool, was much more marked in HIV-2 than HIV-1 infection, despite the clearly better prognosis and the much lower amounts of circulating virus in HIV-2 infection.

A recent report associated the loss of switched B-cells in HIV-1 infection with impairment in the ability of B-cells to respond to IL-2 or other γc cytokines leading to an increase in their susceptibility to apoptosis [4]. Although this possibility was not excluded in the current study of HIV-2-infected patients, our previous data support a relatively better preserved ability to produce
Fig. 3. Serum B-cell activating factor levels in HIV-2 infection. (a) Serum B-cell activating factor (BAFF) levels in HIV-2-infected, HIV-1-infected, and seronegative (Seroneg) individuals. Due to sample availability, a distinct seronegative cohort was used [11 women/six men; 39 (26–61) median years of age; 63.85 (40.10–76.90) median CD4⁺ T-cell frequency; 908 (537–1312) median CD4⁺ T-cells/μl; 8.15 (2.56–18.19) median B-cell frequency; 163 (63–383) median B-cells/μl], as well as representative subgroups of the infected cohorts [HIV-2, including the 10 treated individuals: 13 women/nine men; 56 (19–72) median years of age; 28.02 (4.51–63.20) median CD4⁺ T-cell frequency; 337 (52–1336) median CD4⁺ T-cells/μl; 200 (200–34314) median RNA copies per millilitre; 108 (5–1002) median proviral DNA copies per 10⁶ PBMC; 7.41 (2.89–19.70) median B-cell frequency; 132 (30–369) median B-cells per microlitre; and untreated HIV-1: three women/nine men; 42 (23–61) median years of age; 32.85 (7.71–74.4) median CD4⁺ T-cell frequency; 431 (77–1425) median CD4⁺ T-cells/μl; 1.4 × 10⁵ (40–4.5 × 10⁵) RNA copies per millilitre; 88 (5–573) median proviral DNA copies per 10⁶ PBMC; 6.64 (2.08–15.60) median B-cell frequency; 112 (56–324) median B-cells per microlitre]. (b) The HIV-2 cohort was further stratified according to disease stage (early: >350 CD4⁺ T-cells/μl; late: <350 CD4⁺ T-cells/μl) and levels of plasma viral load (aviremic: undetectable; viremic: detectable), and the BAFF levels were compared between seronegatives and all groups of HIV-2-infected individuals. Each dot represents one individual and bars indicate median. Filled circles refer to antiretroviral therapy (ART)-treated individuals. Statistical analysis was performed using the Mann–Whitney test and the significant P values are shown.
and respond to γc cytokines in HIV-2, as compared to HIV-1 infection [39–41].

The marked levels of switched memory B-cell depletion in HIV-2 infection were unlikely to be solely attributable to loss of the small subset of IgM-only (CD27+ IgD−/− IgM+) memory B-cells [42,43]. Nevertheless, it would be of interest to address in future studies the detailed phenotype of memory B-cells, including levels of expression of IgM and CD21, whose loss has been associated with ongoing HIV replication and disease progression in HIV-1-infected individuals [35].

It is also possible that cell redistribution contributed, at least in part, to the reduction of circulating memory B-cells, emphasizing the relevance of tissue studies. Moreover, given the expected prolonged length of HIV-2 disease, it is plausible that the marked loss of switched memory B-cells may be related to cumulative lymphoid tissue damage, and consequent disruption of the generation of germinal centres where these cells are produced, and/or of the microenvironment required for their survival, ultimately reaching an irreversible level. Accordingly, a more marked switched memory B-cell loss was found in HIV-2-infected patients under long-term antiretroviral treatment, who were estimated to have been infected for a longer period of time.

To our knowledge, there are no data on HIV-2-infected secondary lymphoid organs (SLO). The persistent immune activation observed during HIV-2 infection [12] may be associated with SLO inflammation and collagen deposition with progressive disruption of their architecture, as has been described during HIV-1 infection [44]. HIV-1 has been shown to mainly reside in lymphoid tissues, trapped in the follicular dendritic cell (FDC) network, potentially contributing to progressive disruption of germinal centre responses and limiting the survival signals required for memory B-cell maintenance [45,46]. It is also possible that low levels of HIV-2 replication occur in SLO, contributing to the hyper-activated immune state and the putative progressive tissue damage. In fact, the cytotoxicity documented upon HIV-2 infection of human lymphoid tissue explant cultures was shown to be comparable to that observed for HIV-1 [47].

Importantly, we and others have reported similar levels of cell-associated viral burden in HIV-1-infected and HIV-2-infected patients, as assessed by the levels of proviral DNA within PBMC [31–33]. Thus, the ability to disseminate and establish a reservoir of infected cells is apparently similar in both infections. Furthermore, we have recently provided evidence of a significant degree of ongoing viral replication in HIV-2-infected individuals based on the levels of viral gag and tat gene transcripts within PBMC [31]. These data raised questions about the control of HIV-2 latency. It is plausible that HIV-2 continuously replicates in SLO at low levels, possibly by cell-to-cell mediated transmission. In spite of this putative HIV-2 replication being locally contained, given the reduced viremia, it may have a long-term impact, contributing to accelerated immune senescence. Additionally, it may contribute to the poor immunological recovery that is usually observed in HIV-2-infected patients receiving ART [20,31,48,49], highlighting the importance of rethinking the guidelines on when to start ART in HIV-infected patients [50].

Our findings are particularly relevant in view of the cumulative data suggesting that HIV-1-infected patients under apparently effective ART have significant degrees of replication in SLO [51,52]. These low levels of viral replication were suggested to contribute to a proinflammatory state and to the related complications found in long-term treated HIV-1-infected patients [52].

Notably, in spite of the reduced amounts of plasma HIV-2 load, irrespective of disease stage, we found that the presence of detectable viremia was associated with significantly lower levels of memory B-cells. These results suggest a direct role of the free virions in B-cell disturbances. Alternatively, the presence of detectable virus may itself represent indirect evidence for the disruption of the FDC network, which eventually becomes unable to contain the produced virions.

BAFF has been shown to be critical for B-cell maturation and survival upon bone-marrow egress [36]. Of note, we found that serum BAFF levels were increased in HIV-2-infected patients, particularly in association with viremia, in agreement with previous reports in HIV-1 infection [37,38]. Moreover, HIV-2-infected individuals under ART, who had longer follow-up, featured significant increases in BAFF levels irrespective of viremia, which may contribute to their heightened inflammatory state and B-cell imbalances, as has been suggested in HIV-1 infection [8,37,38,54].

Overall, we showed, for the first time, that despite the reduced amount of circulating virus, HIV-2 infection is associated with a marked depletion of both switched and unswitched memory B-cells, in association with an increase in serum BAFF levels. Our data provide evidence that prolonged HIV disease, even in the absence of detectable viremia, leads to an irreversible damage of memory B-cell homeostasis.

Acknowledgements

We gratefully acknowledge the collaboration of the following colleagues: E. Valadas, F. Antunes, M. Doroana, M. Lucas, and S. Sousa.
R. T. designed and performed experiments, analyzed data and wrote the article; S.F. analyzed data; R.B.F., J.M.M., N.T., R.S.S., A.P.B., R.C. and P.G. performed experiments; R.M.M.V. contributed to the design of the study and data interpretation; A.E.S. designed the research and wrote the article.

This work was supported by grant (PIC/IC/82712/2007) from ‘Fundação para a Ciência e a Tecnologia’ (FCT) and by ‘Programa Operacional Ciência e Inovação 2010’ (POCI2010), as well as by Fundação Calouste Gulbenkian to AES. RT, RBF, RSS, and RC received scholarships from FCT.

Conflicts of interest
The authors have no conflicting financial interests.

References


